© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to May
selective S1PR2 antagonist preclin. candidate
oral efficacy (1 mpk BID) in fibrosis model
scaffold hop from literature starting points
J. Med. Chem., May 3, 2021
Galapagos NV, Mechelen, Belgium
The Galapagos S1PR2 antagonist GLPG2938 is a preclinical candidate intended for the treatment of idiopathic pulmonary fibrosis (IPF). Though several S1PR1 modulators have been approved, no selective S1PR2 antagonist has entered…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.